{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:32:27Z","timestamp":1780446747055,"version":"3.54.1"},"reference-count":17,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2023,10,15]]},"DOI":"10.2169\/internalmedicine.1425-22","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T22:10:10Z","timestamp":1678227010000},"page":"3005-3011","source":"Crossref","is-referenced-by-count":4,"title":["Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat"],"prefix":"10.2169","volume":"62","author":[{"given":"Nozomi","family":"Harai","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ichijo","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, National Hospital Organization, Matsumoto National Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Uchinuma","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuto","family":"Hanihara","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichiro","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, University of Yamanashi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 83: 6-15, 2004.","DOI":"10.1016\/j.ymgme.2004.08.015"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Nilsson O, Svennerholm L. Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem 39: 709-718, 1982.","DOI":"10.1111\/j.1471-4159.1982.tb07950.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Lukina E, Watman N, Dragosky M, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 trial results after 4 years of treatment. Blood Cells Mol Dis 53: 274-276, 2014.","DOI":"10.1016\/j.bcmd.2014.04.002"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cox TM, Drelichman G, Cravo R, et al. Eliglustat compared with imiglucerase in patients with Gaucher's disease type 1 stabilised on enzyme replacement therapy: a phase 3, randomized, open-label, non-inferiority trial. Lancet 385: 2355-2362, 2015.","DOI":"10.1016\/S0140-6736(14)61841-9"},{"key":"5","unstructured":"5. The International Collaborative Gaucher Group. Gaucher Registry 2010 Annual Report (Data cutoff 31 Dec. 2009). Gen-zyme 2010."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tajima A, Yokoi T, Ariga M, et al. Clinical and genetic study of Japanese patients with type 3 Gaucher disease. Mol Genet Metab 97: 272-277, 2009.","DOI":"10.1016\/j.ymgme.2009.05.001"},{"key":"7","unstructured":"7. Horowitz M, Tzuri G, Eyal N, et al. Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. Am J Hum Genet 53: 921-930, 1993."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ida H, Rennert OM, Kawame H, Maekawa K, Eto Y. Mutation prevalence among 47 unrelated Japanese patients with Gaucher disease: identification of four novel mutations. J Inherit Metab Dis 20: 67-73, 1997.","DOI":"10.1023\/A:1005313724361"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Vaca GF, Lenz T, Knight EMP, Tuxhorn I. Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam. Epileptic Disord 14: 155-158, 2012.","DOI":"10.1684\/epd.2012.0501"},{"key":"10","unstructured":"10. Ida H, Eto Y, Tanaka A. [Drug Clinics Efficacy and safety of Cerezyme in Japanese patients with Gaucher disease (types I, II, and III) based on the results of an 8-year post-marketing surveillance]. Shounikasinryou (J Pediatr Pract) 76: 1325-1334, 2013 (in Japanese)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 84: 208-214, 2009.","DOI":"10.1002\/ajh.21362"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105: 4569-4572, 2005.","DOI":"10.1182\/blood-2004-12-4672"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Zimran A, Liphshitz I, Barchana M, Abrahamov A, Elstein D. Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34: 197-200, 2005.","DOI":"10.1016\/j.bcmd.2005.03.004"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type I Gaucher disease: an expert consensus document from the European working group on Gaucher disease. Blood Cells Mol Dis 68: 203-208, 2018.","DOI":"10.1016\/j.bcmd.2016.10.008"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 9: 139-150, 2008.","DOI":"10.1038\/nrm2329"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Cheung WC, Van Ness B. Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells. Leukemia 16: 1182-1188, 2002.","DOI":"10.1038\/sj.leu.2402481"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pavlova EV, Archer J, Wang S, et al. Inhibition of UDP-glucosylceramide synthase in mice prevents Gaucher disease-associated B-cell malignancy. J Pathol 235: 113-124, 2015.","DOI":"10.1002\/path.4452"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/20\/62_1425-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T03:25:34Z","timestamp":1697858734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/62\/20\/62_1425-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":17,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1425-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]},"article-number":"1425-22"}}